<SEC-DOCUMENT>0001140361-25-023976.txt : 20250627
<SEC-HEADER>0001140361-25-023976.hdr.sgml : 20250627
<ACCEPTANCE-DATETIME>20250627162723
ACCESSION NUMBER:		0001140361-25-023976
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250627
FILED AS OF DATE:		20250627
DATE AS OF CHANGE:		20250627

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
		CENTRAL INDEX KEY:			0001615258
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			F4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34483
		FILM NUMBER:		251086754

	BUSINESS ADDRESS:	
		STREET 1:		BUILDING A
		STREET 2:		NO. 1289 YISHAN ROAD
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200233
		BUSINESS PHONE:		86 21 33987870

	MAIL ADDRESS:	
		STREET 1:		BUILDING A
		STREET 2:		NO. 1289 YISHAN ROAD
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200233

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Fosun Pharma USA Inc.
		CENTRAL INDEX KEY:			0002071437
		ORGANIZATION NAME:           	
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34483
		FILM NUMBER:		251086753

	BUSINESS ADDRESS:	
		STREET 1:		104 CARNEGIE CENTER DRIVE
		STREET 2:		SUITE 204
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		609-250-2802

	MAIL ADDRESS:	
		STREET 1:		104 CARNEGIE CENTER DRIVE
		STREET 2:		SUITE 204
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NATURES SUNSHINE PRODUCTS INC
		CENTRAL INDEX KEY:			0000275053
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				870327982
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2901 WEST BLUEGRASS BLVD.
		STREET 2:		SUITE 100
		CITY:			LEHI
		STATE:			UT
		ZIP:			84043
		BUSINESS PHONE:		(801) 341-7900

	MAIL ADDRESS:	
		STREET 1:		2901 WEST BLUEGRASS BLVD.
		STREET 2:		SUITE 100
		CITY:			LEHI
		STATE:			UT
		ZIP:			84043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMTEC INDUSTRIES INC
		DATE OF NAME CHANGE:	19821108
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-06-27</periodOfReport>

    <notSubjectToSection16>true</notSubjectToSection16>

    <issuer>
        <issuerCik>0000275053</issuerCik>
        <issuerName>NATURES SUNSHINE PRODUCTS INC</issuerName>
        <issuerTradingSymbol>NATR</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001615258</rptOwnerCik>
            <rptOwnerName>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>BUILDING A,</rptOwnerStreet1>
            <rptOwnerStreet2>NO. 1289 YISHAN ROAD</rptOwnerStreet2>
            <rptOwnerCity>SHANGHAI</rptOwnerCity>
            <rptOwnerState>F4</rptOwnerState>
            <rptOwnerZipCode>200233</rptOwnerZipCode>
            <rptOwnerStateDescription>CHINA</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002071437</rptOwnerCik>
            <rptOwnerName>Fosun Pharma USA Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>104 CARNEGIE CENTER DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE 204</rptOwnerStreet2>
            <rptOwnerCity>PRINCETON</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08540</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-06-27</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>2854607</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>11.46</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>by Fosun Pharma USA Inc.</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>64167</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>by Fosun Industrial Co., Limited</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The shares were sold pursuant to that certain Underwriting Agreement. dated June 25, 2025, among Fosun Pharma USA Inc., the Issuer, and the underwriter party thereto.</footnote>
        <footnote id="F2">Fosun Pharma USA Inc. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</footnote>
        <footnote id="F3">Fosun Industrial Co., Limited is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. By: /s/ Yuqing Chen, Chairman</signatureName>
        <signatureDate>2025-06-27</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>Fosun Pharma USA Inc.  By: /s/ Yuqing Wang, Chief Financial Officer</signatureName>
        <signatureDate>2025-06-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
